home / stock / cvac / cvac quote
Last: | $2.74 |
---|---|
Change Percent: | 3.4% |
Open: | $2.69 |
Close: | $2.65 |
High: | $2.74 |
Low: | $2.61 |
Volume: | 210,463 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.74 | $2.69 | $2.65 | $2.74 | $2.61 | 210,463 | 05-02-2024 |
$2.65 | $2.52 | $2.65 | $2.72 | $2.52 | 576,399 | 05-01-2024 |
$2.52 | $2.49 | $2.52 | $2.62 | $2.45 | 538,988 | 04-30-2024 |
$2.52 | $2.33 | $2.52 | $2.54 | $2.33 | 594,435 | 04-29-2024 |
$2.33 | $2.32 | $2.33 | $2.42 | $2.28 | 837,605 | 04-26-2024 |
$2.31 | $2.48 | $2.31 | $2.48 | $2.215 | 1,242,504 | 04-25-2024 |
$2.51 | $2.48 | $2.51 | $2.59 | $2.34 | 1,083,717 | 04-24-2024 |
$2.6 | $2.6 | $2.6 | $2.625 | $2.51 | 607,858 | 04-23-2024 |
$2.53 | $2.51 | $2.53 | $2.58 | $2.44 | 598,792 | 04-22-2024 |
$2.44 | $2.47 | $2.44 | $2.49 | $2.36 | 793,106 | 04-19-2024 |
$2.44 | $2.55 | $2.44 | $2.56 | $2.44 | 712,935 | 04-18-2024 |
$2.57 | $2.7 | $2.57 | $2.7293 | $2.54 | 921,443 | 04-17-2024 |
$2.665 | $2.64 | $2.665 | $2.73 | $2.54 | 474,514 | 04-16-2024 |
$2.65 | $2.92 | $2.65 | $2.92 | $2.61 | 944,201 | 04-15-2024 |
$2.91 | $2.97 | $2.91 | $2.97 | $2.81 | 894,825 | 04-12-2024 |
$2.96 | $2.97 | $2.96 | $3.03 | $2.93 | 431,710 | 04-11-2024 |
$2.95 | $2.95 | $2.95 | $2.99 | $2.875 | 539,115 | 04-10-2024 |
$2.97 | $3.08 | $2.97 | $3.14 | $2.95 | 293,802 | 04-09-2024 |
$3.07 | $3.11 | $3.07 | $3.11 | $2.95 | 479,285 | 04-08-2024 |
$3.06 | $2.97 | $3.06 | $3.155 | $2.93 | 778,651 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
CureVac N.V. Company Name:
CVAC Stock Symbol:
NASDAQ Market:
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMA...